Literature DB >> 22360418

Research priorities in pharmacokinetics.

Geoffrey T Tucker1.   

Abstract

An opinion is expressed on the past, present and future roles of pharmacokinetic-pharmacodynamic research in the context of UK clinical pharmacology. On the basis of its current constitution, it seems unlikely that this area of research will be driven from within academic clinical pharmacology in the UK. Therefore, in order to bring its expertise and experience to bear effectively on the evolving emphasis on translational medicine and modelling and simulation, this community would need to reach out beyond its current preoccupations to increase interactions with the next generation of pharmacokineticists and pharmacometricians.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Mesh:

Year:  2012        PMID: 22360418      PMCID: PMC3391520          DOI: 10.1111/j.1365-2125.2012.04238.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches.

Authors:  Mahmud Tareq Hassan Khan
Journal:  Curr Drug Metab       Date:  2010-05       Impact factor: 3.731

Review 2.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

Review 3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 4.  Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.

Authors:  N Fleeman; Y Dundar; R Dickson; A Jorgensen; S Pushpakom; C McLeod; M Pirmohamed; T Walley
Journal:  Pharmacogenomics J       Date:  2010-09-28       Impact factor: 3.550

5.  Therapeutic drug monitoring-an hypothesis still in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  The value of therapeutic drug monitoring to the practising physician--an hypothesis needing sensible application.

Authors:  I D Watson; A H Thomson
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

7.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

8.  Editorial: Pharmacokinetics--master or servant?

Authors:  C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1973-06       Impact factor: 2.953

9.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

10.  Simulation for clinical research trials: a theoretical outline.

Authors:  Peter G Brindley; William F Dunn
Journal:  J Crit Care       Date:  2009-03-27       Impact factor: 3.425

View more
  1 in total

1.  Challenges and opportunities in the advancement of nanomedicines.

Authors:  Alexander Wei; Jonathan G Mehtala; Anil K Patri
Journal:  J Control Release       Date:  2012-10-12       Impact factor: 9.776

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.